YHC1139

YHC1139 is a preclinical-stage small molecule therapeutic being developed through a collaboration between Yuhan Corporation and ABL Bio. It is specifically designed for the treatment of gastroesophageal reflux disease (GERD). As a small molecule candidate, it is intended to address the underlying causes of acid reflux, potentially by modulating gastric acid secretion or providing esophageal mucosal protection. The drug is part of Yuhan's expanding gastrointestinal pipeline, which leverages the company's historical expertise in acid-related disorders. It is currently in the preclinical phase of development, and specific details regarding its molecular target have not been widely disclosed.